Viatris (VTRS) Change in Receivables (2020 - 2026)
Viatris' (VTRS) quarterly Change in Receivables came in at $126.3 million in Q1 2026, up 175.18% year-on-year from $45.9 million in Q1 2025, and up 146.45% quarter-over-quarter from -$271.9 million in Q4 2025.
Viatris (VTRS) Change in Receivables (2020 - 2026) Analysis & Trends
Viatris' Change in Receivables history runs 7 years deep, the most recent figure standing at $126.3 million for Q1 2026.
- On a quarterly basis, Change in Receivables rose 175.18% year-over-year to $126.3 million in Q1 2026; TTM through Mar 2026 was -$40.3 million, a 91.21% increase from a year earlier, with the FY2025 full-year figure at -$334.6 million, down 11.5% from the prior year.
- Change in Receivables improved to $126.3 million in Q1 2026 per VTRS's latest filing, from -$271.9 million in the prior quarter.
- Across five years, Change in Receivables topped out at $339.2 million in Q4 2022 and bottomed at -$300.5 million in Q4 2024.
- The 5-year median for Change in Receivables is $9.6 million (2025), against an average of -$20.4 million.
- Across the five-year window, Change in Receivables jumped 3361.22% in 2022 and sank 1614.29% in 2025, its largest moves.
- Year by year, Change in Receivables stood at $339.2 million in 2022, then slumped by 124.0% to -$81.4 million in 2023, then plunged by 269.16% to -$300.5 million in 2024, then increased by 9.52% to -$271.9 million in 2025, then surged by 146.45% to $126.3 million in 2026.
- Per Business Quant, the three latest VTRS Change in Receivables figures stand at $126.3 million (Q1 2026), -$271.9 million (Q4 2025), and $95.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -38.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126.30 Mn |
| Mar 31, 2026 | 126.30 Mn |
| Dec 31, 2025 | -271.90 Mn |
| Dec 31, 2025 | -271.90 Mn |
| Sep 30, 2025 | 95.70 Mn |
| Sep 30, 2025 | 95.70 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Mar 31, 2025 | -168.00 Mn |
| Mar 31, 2025 | -168.00 Mn |
| Dec 31, 2024 | -300.50 Mn |
| Dec 31, 2024 | -300.50 Mn |
| Sep 30, 2024 | 33.00 Mn |
| Sep 30, 2024 | 33.00 Mn |
| Jun 30, 2024 | -22.80 Mn |
| Jun 30, 2024 | -22.80 Mn |
| Mar 31, 2024 | -9.80 Mn |
| Mar 31, 2024 | -9.80 Mn |
| Dec 31, 2023 | -81.40 Mn |
| Dec 31, 2023 | -81.40 Mn |